Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 1999

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions
HIV Infections
Interventions
DRUG

Atazanavir

DRUG

Nelfinavir mesylate

DRUG

Stavudine

DRUG

Didanosine

Trial Locations (17)

10003

Beth Israel Med Ctr, New York

10032

Columbia Presbyterian Med Ctr, New York

12208

Albany Med College, Albany

20009

ViRx / Dupont Circle Physicians Group, Washington D.C.

30308

AIDS Research Consortium of Atlanta, Atlanta

35203

Clinsites / Sorra Research Ctr, Birmingham

35294

Univ of Alabama at Birmingham, Birmingham

44106

Case Western Reserve Univ, Cleveland

60612

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

63108

Washington Univ School of Medicine, St Louis

75219

Oak Lawn Physicians Group, Dallas

75235

Univ of Texas Southwestern Med Ctr of Dallas, Dallas

77555

Univ TX Galveston Med Branch, Galveston

80262

Univ of Colorado / Health Science Ctr, Denver

92103

UCSD Treatment Ctr, San Diego

94110

UCSF - San Francisco Gen Hosp, San Francisco

Unknown

Ottawa General Hospital, Ottawa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY